Internal Medicine, Medical Oncology · Union City, NJ
NPI
1801074455
Since 2008
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
2000 West St Ste 205
Union City, NJ, 07087
Phone (201) 751-4004
Groups this clinician bills Medicare through
Medicare paid, 2024
$514K
60,480 services
Medicare patients, 2024
219
Average age 77
Drug cost, 2024
$3.6M
1,205 prescriptions
Company payments, 2025
$144
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Bhavna Gupta was code J1756 (injection, iron sucrose, 1 mg), 36,500 times for 45 patients. In total Bhavna Gupta billed 60,480 services in 49 codes, and Medicare paid $514K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-10-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1756 Injection, iron sucrose, 1 mg | Office | 36,500 | 45 | $0.18 | $6,505 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 4,576 | 56 | $0.09 | $413 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 2,371 | 13 | $0.07 | $173 |
| 96367 Intravenous Infusion, Hydration | Office | 669 | 50 | $23.08 | $15K |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 448 | 56 | $0.65 | $292 |
| 96365 Intravenous Infusion, Hydration | Office | 383 | 49 | $51.26 | $20K |
| 99214 Office E&M - Established | Office | 164 | 92 | $99.43 | $16K |
| 99233 Hospital E&M - Subsequent | Facility | 162 | 57 | $91.06 | $15K |
| 99213 Office E&M - Established | Office | 142 | 61 | $71.20 | $10K |
| J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 114 | 13 | $1.03 | $118 |
| 96361 Intravenous Infusion, Hydration | Office | 93 | 12 | $10.01 | $931 |
| 96413 Chemotherapy Administration | Office | 83 | 14 | $106.86 | $8,869 |
| 99204 Office E&M - New | Office | 45 | 45 | $124.72 | $5,613 |
| 99205 Office E&M - New | Office | 43 | 43 | $170.08 | $7,313 |
| 99223 Hospital E&M - Initial | Facility | 12 | 12 | $131.59 | $1,579 |
By year: 2022 $529K for 68,010 services; 2023 $250K for 58,267 services; 2024 $514K for 60,480 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 30 | 23 | $8.40 | $252 |
Medicare prescription drug claims, 2024
In 2024, the drug Bhavna Gupta prescribed most often to Medicare patients was Keytruda (Pembrolizumab), with 76 prescriptions and refills. In total Bhavna Gupta wrote 1,205 Medicare prescriptions that cost $3.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Keytruda Pembrolizumab | 76 | 76 | Under 11 | $829K |
| Loperamide Loperamide Hcl | 74 | 74 | 29 | $1,785 |
| Anastrozole Generic | 73 | 150 | 17 | $852 |
| Hydroxyurea Generic | 71 | 126 | 14 | $1,034 |
| Prednisone Generic | 60 | 67 | 12 | $230 |
| Xgeva Denosumab | 51 | 55 | Under 11 | $169K |
| Eliquis Apixaban | 50 | 51 | 15 | $29K |
| Ondansetron Hcl Generic | 50 | 50 | 23 | $490 |
| Abiraterone Acetate Generic | 41 | 43 | Under 11 | $143K |
| Neulasta Pegfilgrastim | 39 | 39 | Under 11 | $292K |
| Zoledronic Acid Zoledronic Acid/Mannitol-Water | 25 | 300 | 25 | $3,008 |
| Mvasi Bevacizumab-Awwb | 22 | 22 | Under 11 | $113K |
| Carboplatin Generic | 22 | 22 | Under 11 | $1,233 |
| Acyclovir Generic | 21 | 23 | Under 11 | $49.17 |
| Revlimid Lenalidomide | 20 | 20 | Under 11 | $355K |
Brand drugs: 434 claims; generic drugs: 771 claims; opioid claims: 27.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Bhavna Gupta $144 ($144 in general payments such as food, travel and fees) from 2 companies. The largest payer was Amgen Inc. with $125.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.